Burden Of Hidradenitis Suppurativa In The Brazilian Private Healthcare System
Author(s)
Alessandro Bigoni, PhD1, Carla Tozato, MBA1, Ana Almeida, PhD2, Lays Leonel, PhD2, Vinicius Goularte-Silva, BSc2, Camila Vallilo, PhD3;
1Novartis, V&A and HEOR, São Paulo, Brazil, 2IQVIA, São Paulo, Brazil, 3Novartis, Medical Affairs, São Paulo, Brazil
1Novartis, V&A and HEOR, São Paulo, Brazil, 2IQVIA, São Paulo, Brazil, 3Novartis, Medical Affairs, São Paulo, Brazil
Presentation Documents
OBJECTIVES: This study aimed to estimate the incidence rates, describe the demographic profile, and analyze the healthcare resource utilization of patients with hidradenitis suppurativa (HS) within the Brazilian private healthcare system.
METHODS: This observational, descriptive study utilized a private administrative claims database from the largest private insurer in Brazil, including patients with at least one claim related to the International Classification of Diseases, 10th Revision (ICD-10) code L73.2 from January 2017 to December 2023, with minimal exclusion criteria. Patients were categorized based on the presence (moderate/severe) or absence (mild) of HS-related surgery. Prevalence rates were standardized by the insurer’s coverage in the national territory. The study was reviewed and approved by the Ethics Committee, approval number 82355024.0.0000.8054.
RESULTS: The study included 4,872 HS patients, with estimated incidence rates increasing from 12.2 cases per 100,000 covered individuals in 2017 to 41.2 cases in 2023. Of these patients, 97.9% were classified as mild, while 2.1% were categorized as moderate/severe HS. There was a female predominance (61.2%), with a mean age of 33.4 years (SD 12.8), and 53.8% were aged 18 to 34., The prevalence rates in the population covered by the insurer ranged from 5.2% in the south region to 1.0% in the north region. Among the HS patients, 1,523(31.3%) had at least one HS-related procedure, with a mean number of 5.8(SD 7.1) for mild patients and 12.1 (SD 14.7) for moderate/severe patients. Additionally, 4,869 (99.9%) had at least one HS-related outpatient visit, with 9.6 (SD 13.4) visits for mild patients and 31.4 (SD 32.0) for moderate/severe patients.
CONCLUSIONS: The findings underscore the significant healthcare resource utilization associated with HS, particularly among moderate/severe cases, which had higher number of HS-related procedures and outpatient visits. These results emphasize the need for targeted healthcare strategies to manage HS effectively and reduce its burden on the healthcare system.
METHODS: This observational, descriptive study utilized a private administrative claims database from the largest private insurer in Brazil, including patients with at least one claim related to the International Classification of Diseases, 10th Revision (ICD-10) code L73.2 from January 2017 to December 2023, with minimal exclusion criteria. Patients were categorized based on the presence (moderate/severe) or absence (mild) of HS-related surgery. Prevalence rates were standardized by the insurer’s coverage in the national territory. The study was reviewed and approved by the Ethics Committee, approval number 82355024.0.0000.8054.
RESULTS: The study included 4,872 HS patients, with estimated incidence rates increasing from 12.2 cases per 100,000 covered individuals in 2017 to 41.2 cases in 2023. Of these patients, 97.9% were classified as mild, while 2.1% were categorized as moderate/severe HS. There was a female predominance (61.2%), with a mean age of 33.4 years (SD 12.8), and 53.8% were aged 18 to 34., The prevalence rates in the population covered by the insurer ranged from 5.2% in the south region to 1.0% in the north region. Among the HS patients, 1,523(31.3%) had at least one HS-related procedure, with a mean number of 5.8(SD 7.1) for mild patients and 12.1 (SD 14.7) for moderate/severe patients. Additionally, 4,869 (99.9%) had at least one HS-related outpatient visit, with 9.6 (SD 13.4) visits for mild patients and 31.4 (SD 32.0) for moderate/severe patients.
CONCLUSIONS: The findings underscore the significant healthcare resource utilization associated with HS, particularly among moderate/severe cases, which had higher number of HS-related procedures and outpatient visits. These results emphasize the need for targeted healthcare strategies to manage HS effectively and reduce its burden on the healthcare system.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD139
Topic
Real World Data & Information Systems
Disease
SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)